Abivax (ABVX) Q2 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$1.69

Estimate

-$0.86

Surprise

-97.0%

Score today

6.1/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Abivax (ABVX) reported a wider loss than forecast — adjusted EPS of -$1.69 against the -$0.86 estimate (a 97.0% shortfall).

• Earnings Scheduled For September 21, 2026 — benzinga, 2026-09-21
• Nasdaq Gains Over 100 Points, Posts Weekly Gain: Investor Sentiment Improves Slightly, But Greed Index Remains in ‘Fear’ — benzinga, 2026-09-21
• Accenture, Abivax and 3 Stocks to Watch Heading Into Monday — benzinga, 2026-09-21

TrendMatrix currently rates ABVX Sell at 6.1/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate; this quarter's -97.0% surprise compares with a -77.8% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$103.45

Price target

$143.55

Stop

$98.25

Upside to target

+38.8%

Reward-to-risk

4.1:1

Model outputs from TrendMatrix’s engine as of 2026-09-22 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$9.03B

P/E (fwd)

-31.0

52-week range

$69.81–$148.83

Off 52-week high

30.5%

RSI (14)

41

Volume vs avg

0.89×

Score today

6.1/10